Pmv Pharmaceuticals shares rise 6.29% after-hours after promising Phase 2 clinical trial data for Rezatapopt.

Pmv Pharmaceuticals, Inc. rose 6.29% in after-hours trading, following the announcement of promising interim data from the PYNNACLE Phase 2 pivotal clinical trial for Rezatapopt. The data showed a 33% overall response rate across eight tumor types and a 43% response rate in the ovarian cancer cohort. The company plans to submit a New Drug Application for platinum-resistant/refractory ovarian cancer in the first quarter of 2027.